ADOCIA Confirms Its Eligibility for The PEA – PME
11 July 2020 - 2:00AM
Business Wire
Regulatory News:
ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC – the
“Company”) confirms its eligibility for the “PEA – PME” stock
savings tax regime, which decree has been published in the French
Journal Officiel on March 4, 2014 (Decree n ° 2014-283), and which
entered into force on March 6, 2014.
To be eligible for the “PEA – PME”, the shares must have been
issued by a company whose market capitalization is below one
billion euros, of which no legal person holds more than 25% of its
capital, which has less than 5,000 employees, and an annual
turnover not exceeding 1.5 billion euros or a total balance sheet
less than 2 billion euros.
Adocia meets all of these conditions.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring four clinical-stage products. Adocia
aims to expand its portfolio towards the treatment of other
metabolic diseases and their comorbidities. The proprietary
BioChaperone® technological platform is designed to enhance the
effectiveness and/or safety of therapeutic proteins while making
them easier for patients to use. Adocia customizes BioChaperone to
each protein for a given application. Adocia’s clinical pipeline
includes four novel insulin formulations for prandial treatment of
diabetes: two ultra-rapid formulations of insulin analog lispro
(BioChaperone® Lispro U100 and U200), a combination of basal
insulin glargine and rapid-acting insulin lispro (BioChaperone®
Combo) and one combination of a prandial insulin with amylin analog
pramlintide M1Pram (ADO09).The clinical pipeline also includes an
aqueous formulation of human glucagon (BioChaperone® Glucagon) for
the treatment of hypoglycemia. Adocia preclinical pipeline includes
three products: a combination of rapid human insulin analogues and
Pramlintide (BioChaperone LisPram), a combination of insulin
glargine with GLP-1 receptor agonists (BioChaperone® Glargine
GLP-1) for the treatment of diabetes and a readyto-use combination
of glucagon and a GLP-1 receptor agonist (BioChaperone® Glucagon
GLP1) for the treatment of obesity.
Adocia aims to deliver “Innovative medicine for everyone,
everywhere.”
To learn more about Adocia, please visit us at
www.adocia.com
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Reference Document filed with the
French Autorité des marchés financiers on April 22, 2020 (a copy of
which is available at www.adocia.com) and to the development of
economic conditions, financial markets and the markets in which
Adocia operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Adocia or
not currently considered material by Adocia. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Adocia to be materially
different from such forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200710005180/en/
Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph.: +33 4 72 610
610
Adocia Press Relations Europe MC Services AG
Raimund Gabriel adocia@mc-services.eu
Ph.: +49 89 210 228 0
Adocia Investor Relations USA The Ruth Group Tram
Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2024 to May 2024
Adocia (EU:ADOC)
Historical Stock Chart
From May 2023 to May 2024